Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17473134 | 0.84 | KMT2A (0.54) | NPC1RAB9ALMNAMAPTL3MBTL1 | |
| SCHEMBL15317893 | 0.81 | CA12 (0.55) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL6406957 | 0.81 | CA12 (0.61) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL16558009 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL9972687 | 0.78 | RAB9A (0.51) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL19706606 | 0.78 | MAPT (0.64) | NPC1RAB9ALMNAMAPTL3MBTL1 | |
| SCHEMBL1947879 | 0.76 | ALDH1A1 (0.65) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL11100708 | 0.76 | CA12 (0.63) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL19709254 | 0.76 | HTR2A (0.54) | NPC1RAB9ALMNAMAPTGAA | |
| SCHEMBL4756378 | 0.75 | CA12 (0.58) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11485744-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
| US-20210206782-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | disclosed |
| US-10233197-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2019-03-19 | — | — | US | disclosed |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2018-08-09 | — | — | US | disclosed |
| US-9969751-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-9969751-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2013-01-17 | — | — | US | disclosed |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2012-06-21 | — | — | US | disclosed |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | CA12 622/4885CA1 914/4885CA2 658/4885 |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | CA12 4350/4885CA1 4406/4885CA2 3898/4885 |
| US-20210206782-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | CA12 4391/4885CA1 4418/4885CA2 4009/4885 |
| US-11485744-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | SLC7A1, VIP, HPGDS | CA12 4350/4885CA1 4406/4885CA2 3898/4885 |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | CA12 4350/4885CA1 4406/4885CA2 3898/4885 |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | CA12 4391/4885CA1 4418/4885CA2 4009/4885 |
| US-10233197-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | SLC7A1, VIP, HAMP | CA12 4391/4885CA1 4418/4885CA2 4009/4885 |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | CA12 4391/4885CA1 4418/4885CA2 4009/4885 |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | CA12 4350/4885CA1 4406/4885CA2 3898/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | CA12 183/4885CA1 456/4885CA2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.